AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
FDA completes review of Estrasorb NDA.(Brief Article)
2002 MAY 30 - (NewsRx.com & NewsRx.net) -- Novavax, Inc., (NVAX) announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Estrasorb new drug application (NDA).
During the review process, no issues regarding the efficacy or safety of Estrasorb have been communicated by the review division. The agency has requested additional information with respect to the chemistry manufacturing and controls (CMC) section of the filing.
Based upon ongoing discussions with the FDA, Novavax believes the most advantageous approach to resolving the outstanding CMC questions is to voluntarily withdraw the NDA and resubmit once all the responses to the CMC ...
- Dyax Receives Complete Response Letter from FDA for DX-88 in Acute Attacks of...
- Press release article from: Business Wire March 26, 2009 700+ words
...intends to fully address the FDA's requests in a timely manner...previously submitted to the FDA a proposed Safe Use program...as part of its response. The CMC questions are primarily focused on analytical...the Company's response, the FDA will determine a revised review...
- Penederm announces FDA action on retinoic acid acne products.
- Press release article from: Business Wire April 25, 1995 700+ words
...nonapprovable at this time. The FDA raised issues with respect to...Penederm has notified the FDA that it intends to supply the...additional information regarding the CMC questions raised. The Company believes...Penederm is working with the FDA to clarify the clinical issues...
- Spectrum Pharmaceuticals, Inc. Announces Financial Update and Pipeline Review.
- Press release article from: PR Newswire March 14, 2007 700+ words
...Key Upcoming Milestones * Satraplatin - U.S. FDA approval and commercial launch - European filing...thereafter * LFA (Levofolinic acid) - Submit to the FDA Response on CMC Questions - U.S. FDA approval in 2H07 - Commence combination study with...
- Neoprobe Announces 1998 Second Quarter Results and Provides Business Update.
- Press release article from: Business Wire August 4, 1998 700+ words
...have been determined: -- The FDA is requesting prospective data...findings. -- Neoprobe and the FDA have agreed to a preliminary...data. -- Neoprobe and the FDA have agreed to a plan of action to address the manufacturing CMC questions. -- Neoprobe's BLA will...
- IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status...
- Press release article from: PR Newswire July 1, 2008 700+ words
...addition to responding to the remaining CMC questions. The Company believes that the additional...U.S. Food and Drug Administration (FDA). The Company expects to submit the...States in 2001. The NDA was submitted to FDA in October 2006 and was accepted for review...
- IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status...
- Press release article from: PR Newswire September 26, 2008 700+ words
...INT-0133), in addition to responding to the remaining CMC questions. The Company provided this information in accordance with...Company received from the U.S. Food and Drug Administration (FDA). The Company expects to submit the amended New Drug Application...
- FDA publishes final guidance on voluntary third-party certification....
- Magazine article from: The Food Institute Report February 2, 2009 700+ words
FDA published a final guidance document on voluntary...Foods and Feeds (available at http://www.fda.gov/oc/guidance/third); see also...Comments on the guidance may be submitted to FDA at any time. This guidance describes the general...
- FDA, SEC link up on false statements to public.
- Newspaper article from: Warning Letter Bulletin March 8, 2004 700+ words
Dear Reader, FDA and the Securities and Exchange Com-mission...developed a closer partnership, whereby FDA will provide SEC with information about potential...executives concealed the fact from investors that FDA would not be approving its drug, Erbitux...
